Neuropsychopharmacology Reports (Dec 2022)
Development of individual fitness score for conformity of prescriptions to the “Guidelines For Pharmacological Therapy of Schizophrenia”
- Ken Inada,
- Kentaro Fukumoto,
- Naomi Hasegawa,
- Yuka Yasuda,
- Hisashi Yamada,
- Hikaru Hori,
- Kayo Ichihashi,
- Hitoshi Iida,
- Kazutaka Ohi,
- Hiroyuki Muraoka,
- Fumitoshi Kodaka,
- Kenta Ide,
- Naoki Hashimoto,
- Jun‐ichi Iga,
- Kazuyoshi Ogasawara,
- Kiyokazu Atake,
- Yoshikazu Takaesu,
- Tatsuya Nagasawa,
- Hiroshi Komatsu,
- Tsuyoshi Okada,
- Ryuji Furihata,
- Mikio Kido,
- Saya Kikuchi,
- Chika Kubota,
- Manabu Makinodan,
- Shinichiro Ochi,
- Masahiro Takeshima,
- Hirotaka Yamagata,
- Junya Matsumoto,
- Kenichiro Miura,
- Masahide Usami,
- Taishiro Kishimoto,
- Toshiaki Onitsuka,
- Eiichi Katsumoto,
- Akitoyo Hishimoto,
- Shusuke Numata,
- Norio Yasui‐Furukori,
- Koichiro Watanabe,
- Ryota Hashimoto
Affiliations
- Ken Inada
- Department of Psychiatry, School of Medicine Kitasato University Sagamihara Japan
- Kentaro Fukumoto
- Department of Neuropsychiatry Iwate Medical University Iwate Japan
- Naomi Hasegawa
- Department of Pathology of Mental Diseases, National Institute of Mental Health National Center of Neurology and Psychiatry Tokyo Japan
- Yuka Yasuda
- Department of Pathology of Mental Diseases, National Institute of Mental Health National Center of Neurology and Psychiatry Tokyo Japan
- Hisashi Yamada
- Department of Neuropsychiatry Hyogo Medical College Hyogo Japan
- Hikaru Hori
- Department of Psychiatry Faculty of Medicine Fukuoka University Fukuoka Japan
- Kayo Ichihashi
- Department of Neuropsychiatry University of Tokyo Hospital Tokyo Japan
- Hitoshi Iida
- Department of Psychiatry Faculty of Medicine Fukuoka University Fukuoka Japan
- Kazutaka Ohi
- Department of Psychiatry Gifu University Graduate School of Medicine Gifu Japan
- Hiroyuki Muraoka
- Department of Psychiatry Tokyo Women's Medical University Tokyo Japan
- Fumitoshi Kodaka
- Department of Psychiatry The Jikei University School of Medicine Tokyo Japan
- Kenta Ide
- Department of Hospital Pharmacy Hospital of University of Occupational and Environmental Health Fukuoka Japan
- Naoki Hashimoto
- Department of Psychiatry Hokkaido University Graduate School of Medicine Hokkaido Japan
- Jun‐ichi Iga
- Department of Neuropsychiatry Ehime University Graduate School of Medicine Ehime Japan
- Kazuyoshi Ogasawara
- Center for Postgraduate Clinical Training and Career Development Nagoya University Hospital Achi Japan
- Kiyokazu Atake
- Nippon Telegraph and Telephone West Corporation Kyushu Health Administration Center Fukuoka Japan
- Yoshikazu Takaesu
- Department of Neuropsychiatry, Graduate School of Medicine University of the Ryukyus Okinawa Japan
- Tatsuya Nagasawa
- Department of NeuroPsychiatry Kanazawa Medical University Ishikawa Japan
- Hiroshi Komatsu
- Department of Psychiatry Tohoku University Hospital Miyagi Japan
- Tsuyoshi Okada
- Department of Psychiatry Jichi Medical University Tochigi Japan
- Ryuji Furihata
- Agency for Student Support and Disability Resources Kyoto University Kyoto Japan
- Mikio Kido
- Kido Clinic Toyama Japan
- Saya Kikuchi
- Department of Psychiatry Tohoku University Hospital Miyagi Japan
- Chika Kubota
- Department of Psychiatry, National Center Hospital National Center of Neurology and Psychiatry Tokyo Japan
- Manabu Makinodan
- Department of Psychiatry Nara Medical University Nara Japan
- Shinichiro Ochi
- Department of Neuropsychiatry, Molecules and Function Ehime University Graduate School of Medicine Ehime Japan
- Masahiro Takeshima
- Department of Neuropsychiatry Akita University Graduate School of Medicine Akita Japan
- Hirotaka Yamagata
- Division of Neuropsychiatry Department of Neuroscience Yamaguchi University School of Medicine Yamaguchi Japan
- Junya Matsumoto
- Department of Pathology of Mental Diseases, National Institute of Mental Health National Center of Neurology and Psychiatry Tokyo Japan
- Kenichiro Miura
- Department of Pathology of Mental Diseases, National Institute of Mental Health National Center of Neurology and Psychiatry Tokyo Japan
- Masahide Usami
- Department of Child and Adolescent Psychiatry, Kohnodai Hospital National Center for Global Health and Medicine Chiba Japan
- Taishiro Kishimoto
- Hills Joint Research Laboratory for Future Preventive Medicine and Wellness Keio University School of Medicine Tokyo Japan
- Toshiaki Onitsuka
- Department of Neuroimaging Psychiatry, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
- Eiichi Katsumoto
- Katsumoto Mental Clinic Osaka Japan
- Akitoyo Hishimoto
- Department of Psychiatry Yokohama City University Graduate School of Medicine Kanagawa Japan
- Shusuke Numata
- Department of Psychiatry, Graduate School of Biomedical Science Tokushima University Tokushima Japan
- Norio Yasui‐Furukori
- Department of Psychiatry Dokkyo Medical University School of Medicine Tochigi Japan
- Koichiro Watanabe
- Department of Neuropsychiatry, School of Medicine Kyorin University Tokyo Japan
- Ryota Hashimoto
- Department of Pathology of Mental Diseases, National Institute of Mental Health National Center of Neurology and Psychiatry Tokyo Japan
- DOI
- https://doi.org/10.1002/npr2.12293
- Journal volume & issue
-
Vol. 42,
no. 4
pp. 502 – 509
Abstract
Abstract Aims The Guidelines for the Pharmacotherapy of Schizophrenia were established to improve the quality of medical care, and the EGUIDE project was conducted to train clinicians on guideline usage. A quality indicator (QI) was established to measure the prevalence of the guidelines, and a survey was conducted, which revealed a gap between the guidelines and actual clinical practice (evidence‐practice‐gap). The purpose of this study was to develop an individual fitness score (IFS) formula that expresses the degree to which prescribers adhere to the Guidelines for Pharmacological Therapy of Schizophrenia in a simple manner, and to determine the validity of this formula from a survey of the prescriptions of the EGUIDE project participants'. Methods To establish appropriate scores, members discussed the proposed formula and then voted on them. The IFS formula developed was set up so that antipsychotic monotherapy would be given 100 points, with points deducted if concomitant or adjunctive antipsychotic medications were used, and a minimum score of 0. To validate this formula, prescriptions of hospitalized schizophrenic patients at admission and at discharge were scored and compared. Result IFS points vary and ranged from 0 to100. The average pre‐admission score for all subjects was 45.6, and the average score at discharge was 54, those were significantly higher during discharge. Conclusions We developed an IFS formula, a tool to easily visualize the degree to which current prescriptions conform to the guidelines for the pharmacological treatment of schizophrenia.
Keywords
- clinical practice guideline
- individual fitness score (IFS)
- prescription
- quality indicator
- schizophrenia
